209 related articles for article (PubMed ID: 37883802)
1. Reciprocal stabilization of coagulation factor XIII-A and -B subunits is a determinant of plasma FXIII concentration.
Byrnes JR; Lee T; Sharaby S; Campbell RA; Dobson DA; Holle LA; Luo M; Kangro K; Homeister JW; Aleman MM; Luyendyk JP; Kerlin BA; Dumond JB; Wolberg AS
Blood; 2024 Feb; 143(5):444-455. PubMed ID: 37883802
[TBL] [Abstract][Full Text] [Related]
2. Free factor XIII activation peptide (fAP-FXIII) is a regulator of factor XIII activity via factor XIII-B.
Dodt J; Pasternack R; Seitz R; Volkers P
Br J Haematol; 2016 Feb; 172(3):452-60. PubMed ID: 26516704
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.
Lovejoy AE; Reynolds TC; Visich JE; Butine MD; Young G; Belvedere MA; Blain RC; Pederson SM; Ishak LM; Nugent DJ
Blood; 2006 Jul; 108(1):57-62. PubMed ID: 16556896
[TBL] [Abstract][Full Text] [Related]
4. Comparison of F13A1 gene mutations in 73 patients treated with recombinant FXIII-A
Ivaškevičius V; Biswas A; Garly ML; Oldenburg J
Haemophilia; 2017 May; 23(3):e194-e203. PubMed ID: 28520207
[TBL] [Abstract][Full Text] [Related]
5. Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice.
Souri M; Koseki-Kuno S; Takeda N; Degen JL; Ichinose A
Int J Hematol; 2008 Jan; 87(1):60-8. PubMed ID: 18224415
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic characterization of recombinant factor XIII (FXIII)-A2 across age groups in patients with FXIII A-subunit congenital deficiency.
Brand-Staufer B; Carcao M; Kerlin BA; Will A; Williams M; Tornøe CW; Sandberg Lundblad M; Nugent D
Haemophilia; 2015 May; 21(3):380-385. PubMed ID: 25643920
[TBL] [Abstract][Full Text] [Related]
7. Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results.
Kerlin BA; Inbal A; Will A; Williams M; Garly ML; Jacobsen L; Kearney SL
J Thromb Haemost; 2017 Aug; 15(8):1601-1606. PubMed ID: 28581691
[TBL] [Abstract][Full Text] [Related]
8. Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency.
Carcao M; Altisent C; Castaman G; Fukutake K; Kerlin BA; Kessler C; Lassila R; Nugent D; Oldenburg J; Garly ML; Rosholm A; Inbal A
Thromb Haemost; 2018 Mar; 118(3):451-460. PubMed ID: 29448295
[TBL] [Abstract][Full Text] [Related]
9. The interaction between fibrinogen and zymogen FXIII-A2B2 is mediated by fibrinogen residues γ390-396 and the FXIII-B subunits.
Byrnes JR; Wilson C; Boutelle AM; Brandner CB; Flick MJ; Philippou H; Wolberg AS
Blood; 2016 Oct; 128(15):1969-1978. PubMed ID: 27561317
[TBL] [Abstract][Full Text] [Related]
10. Factor XIII topology: organization of B subunits and changes with activation studied with single-molecule atomic force microscopy.
Protopopova AD; Ramirez A; Klinov DV; Litvinov RI; Weisel JW
J Thromb Haemost; 2019 May; 17(5):737-748. PubMed ID: 30773828
[TBL] [Abstract][Full Text] [Related]
11. Interaction of factor XIII subunits.
Katona E; Pénzes K; Csapó A; Fazakas F; Udvardy ML; Bagoly Z; Orosz ZZ; Muszbek L
Blood; 2014 Mar; 123(11):1757-63. PubMed ID: 24408323
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency.
Kerlin B; Brand B; Inbal A; Halimeh S; Nugent D; Lundblad M; Tehranchi R
J Thromb Haemost; 2014 Dec; 12(12):2038-43. PubMed ID: 25263390
[TBL] [Abstract][Full Text] [Related]
13. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function.
Muszbek L; Adány R; Mikkola H
Crit Rev Clin Lab Sci; 1996; 33(5):357-421. PubMed ID: 8922891
[TBL] [Abstract][Full Text] [Related]
14. Severe bleeding diatheses in an elderly patient with combined type autoantibody against factor XIII A subunit; novel approach to the diagnosis and classification of anti-factor XIII antibodies.
Kun M; Szuber N; Katona É; Pénzes K; Bonnefoy A; Bécsi B; Erdődi F; Rivard GE; Muszbek L
Haemophilia; 2017 Jul; 23(4):590-597. PubMed ID: 28345289
[TBL] [Abstract][Full Text] [Related]
15. Antibodies against Noncatalytic B Subunit of Factor XIII Inhibit Activation of Factor XIII and Fibrin Crosslinking.
Souri M; Yokoyama C; Osaki T; Ichinose A
Thromb Haemost; 2023 Sep; 123(9):841-854. PubMed ID: 36934722
[TBL] [Abstract][Full Text] [Related]
16. Sustained depletion of FXIII-A by inducing acquired FXIII-B deficiency.
Strilchuk AW; Meixner SC; Leung J; Safikhan NS; Kulkarni JA; Russell HM; van der Meel R; Sutherland MR; Owens AP; Palumbo JS; Conway EM; Pryzdial ELG; Cullis PR; Kastrup CJ
Blood; 2020 Dec; 136(25):2946-2954. PubMed ID: 32678423
[TBL] [Abstract][Full Text] [Related]
17. Severe congenital factor XIII deficiency caused by novel W187X and G273V mutations in the F13A gene; diagnosis and classification according to the ISTH/SSC guidelines.
Souri M; Biswas A; Misawa M; Omura H; Ichinose A
Haemophilia; 2014 Mar; 20(2):255-62. PubMed ID: 24286209
[TBL] [Abstract][Full Text] [Related]
18. Let's cross-link: diverse functions of the promiscuous cellular transglutaminase factor XIII-A.
Mitchell JL; Mutch NJ
J Thromb Haemost; 2019 Jan; 17(1):19-30. PubMed ID: 30489000
[TBL] [Abstract][Full Text] [Related]
19. Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes.
Carcao M; Fukutake K; Inbal A; Kerlin B; Lassila R; Oldenburg J; Garly ML; Nugent D
Semin Thromb Hemost; 2017 Feb; 43(1):59-68. PubMed ID: 27556350
[TBL] [Abstract][Full Text] [Related]
20. Factor XIII: Structure and Function.
Schroeder V; Kohler HP
Semin Thromb Hemost; 2016 Jun; 42(4):422-8. PubMed ID: 27019464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
